Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma
Primary Purpose
Ewing's Sarcoma
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Vincristine, Actinomycin-D, Ifosfamide
Sponsored by
About this trial
This is an interventional treatment trial for Ewing's Sarcoma
Eligibility Criteria
Inclusion Criteria:
- Patients with Ewing's Sarcoma
Sites / Locations
Outcomes
Primary Outcome Measures
Efficacy
Secondary Outcome Measures
Full Information
NCT ID
NCT00541411
First Posted
October 9, 2007
Last Updated
April 16, 2012
Sponsor
King Faisal Specialist Hospital & Research Center
1. Study Identification
Unique Protocol Identification Number
NCT00541411
Brief Title
Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma
Study Type
Interventional
2. Study Status
Record Verification Date
April 2012
Overall Recruitment Status
Unknown status
Study Start Date
June 2003 (undefined)
Primary Completion Date
June 2013 (Anticipated)
Study Completion Date
June 2013 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
King Faisal Specialist Hospital & Research Center
4. Oversight
5. Study Description
Brief Summary
Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide combination chemotherapy in Ewing's Sarcoma
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ewing's Sarcoma
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Vincristine, Actinomycin-D, Ifosfamide
Intervention Description
Chemotherapy
Primary Outcome Measure Information:
Title
Efficacy
Time Frame
overall
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with Ewing's Sarcoma
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Muhammad Memon, MD
Organizational Affiliation
King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma
We'll reach out to this number within 24 hrs